ReveraGen Receives $3.3 Million NIH Grant for NDA Preparations for Vamorolone in Duchenne
The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded a $3.3 million grant to ReveraGen Inc. to support the advancement of vamorolone towards FDA submission and…Learn More